XOMA Corp. Stock
XOMA Corp. Stock
There is no change in the price for XOMA Corp. today.
XOMA Corp. is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
Based on the current price of 26.6 € the target price of 98 € shows a potential of 268.42% for XOMA Corp. which would more than double the current price.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for XOMA Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of XOMA Corp. in the next few years
Pros
?
B****
?
M***** P*******
?
C******** o* t** e**********
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of XOMA Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| XOMA Corp. | 0.000% | -5.000% | -6.338% | -12.500% | 8.130% | 34.343% | -1.990% |
| Ardelyx Inc. | -0.470% | 1.501% | -0.696% | -1.154% | 3.525% | 187.536% | -1.306% |
| Krystal Biotech | 5.350% | 6.399% | 15.665% | 18.562% | 32.194% | 164.737% | - |
| Evolus Inc | 0.890% | -5.042% | -1.739% | -52.521% | -46.190% | -16.296% | 86.346% |
Comments
XOMA Royalty (NASDAQ:XOMA) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.
Show more
Ratings data for XOMA provided by MarketBeat
XOMA Co. (NASDAQ: XOMA) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for XOMA provided by MarketBeat
XOMA Co. (NASDAQ: XOMA) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for XOMA provided by MarketBeat
News
XOMA Revenue Jumps 39% in Fiscal Q2
XOMA (NASDAQ:XOMA), a biotechnology royalty aggregator, reported second quarter results on August 13, 2025, for the period ending June 30. The company’s revenue (GAAP) reached $13.1 million for Q2
